鬆景科技(01079.HK)擬向肇慶維超智能科技注資 料持不超15%股權
格隆匯12月3日丨鬆景科技(01079.HK)公告,於2019年12月3日,公司與目標公司肇慶市維超智能科技有限公司訂立諒解備忘錄,內容有關向目標公司的可能注資,因此,於完成後,預計公司將持有目標公司不超過15%的股權。
目標公司為一間於中國成立的公司,主要從事研發裸眼3D技術及相關產品。其產品及服務包括用於手機及平板電腦等電子設備的裸眼3D屏幕保護、裸眼3D顯示器廣告燈箱、裸眼3D多屏顯示器牆及裸眼3D巨型LED屏幕。目標公司的出資額有待本公司、目標公司及目標公司全體股東進一步磋商,並預期由公司以現金方式或本公司、目標公司及目標公司全體股東協定的其他形式代價支付。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.